VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events…
VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events…
– Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains…
– Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains…
BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
Roger Estafanos ITM announces a new General Manager for U.S. ITM U.S. Headquarters ITM Opens…
Roger Estafanos ITM announces a new General Manager for U.S. ITM U.S. Headquarters ITM Opens…
Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023 BOSTON, April 17,…
Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023 BOSTON, April 17,…
Compounds that activate SERCA2a may lead to novel therapies for heart failure WARRINGTON, Pa., April…
Compounds that activate SERCA2a may lead to novel therapies for heart failure WARRINGTON, Pa., April…
Sales, Customer Support, and Market Access Teams Grow to Meet Rising Demand for Near-Patient Solutions…
Sales, Customer Support, and Market Access Teams Grow to Meet Rising Demand for Near-Patient Solutions…
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived…
VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived…
NEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage…
NEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage…